CSPC Megalith Biopharmaceutical Co. Ltd. has described antibody-drug conjugates (ADCs) comprising anti-tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) antibodies covalently linked to cytotoxic drugs reported to be useful for the treatment of pancreatic and breast cancer.
Takeda Pharmaceutical Co. Ltd. has divulged polypeptides acting as gastric inhibitory polypeptide receptor (GIPR) agonists reported to be useful for the treatment of nausea and vomiting.
Lifemine Therapeutics Inc. has identified serine/threonine-protein phosphatase 2B (PPP3CC; PP2Bγ; calcineurin) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome (SARS), fungal infections, transplant rejection, and dermatological, respiratory and eye disorders.
Maplight Therapeutics Inc. has synthesized G protein-coupled receptor GPR6 inverse agonists reported to be useful for the treatment of anxiety, bipolar disorder, eating disorders, depression, schizophrenia, Huntington’s disease, Parkinson’s disease and Alzheimer’s disease, among others.
Siteone Therapeutics Inc. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Some Apple Watch users will be able to monitor their blood oxygen levels through their iPhone, thanks to a software update the company planned to issue Aug. 14. The Cupertino, Calif.-based company pulled the feature from its watches in the U.S. in 2024, following a patent dispute with Masimo Corp., of Irvine, Calif., that threatened an import ban.
Etern Therapeutics (Wuxi) Co. Ltd. has divulged polycyclic compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of ischemia-reperfusion injury.
RSS
